ECCO 2026

Precision medicine - from a static to a dynamic system

IL-23 - is this the good-bye from systemic therapy?

Early treatment concepts with infliximab

Update on upadacitinib vs. risankizumab after anti-TNF…

Fistulizing disease - what can we do better?

IL-23: from real-world to special patient population

Deeper endpoints in clincial trials and RW

Evolving landscape of anti-fibrotic therapy in IBD

Long-term data on colorectal cancer risk in modern IBD…

Exciting new data on surgery - for all patient groups?

What is the best treatment approach in IBD?

Switching to subcutaneous infliximab is safe as a…

Molecular medicine driving treatment decisioning!?

Molecular signature–driven therapy

Stop of thiopurines in patients on subcutaneous…

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

Molekulare Medizin als Wegweiser für…

Was ist der beste Therapieansatz bei CED?

JAK–STAT inhibition as a therapeutic approach for…

Early use of infliximab positively influences longterm…

LIR!C 10 yrs FUP: Is there a benefit for surgery?

Long-term risankizumab persistence

Should we prevent or treat post-operative recurrence in…

Top-down vs. step-up therapy in CD

JAK-STAT Hemmung zur Fistel-Therapie

Top-down vs. Step-up Therapie beim Morbus Crohn

Is onmiddellijke postoperatieve preventie nodig?

Früher Einsatz von Infliximab verbessert das…

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

Treat-2-target strategy in UC

Long term outcomes after appendicectomy in UC (5 year…

ASUC: smarter use of third-line rescue therapy

Steroid sparing effect of filgotinib in UC

Combination therapy with tofacitinib and…

Strategia treat-to-target nella colite ulcerosa

Tofacitinib-Steroid-Kombination bei ASUC

Effetto steroid-sparing di filgotinib nella colite…

ASUC: Derde‑lijn­therapie slimmer inzetten

Pouchchirurgie: enkel voor expertisecentra

The risk of colorectal neoplasia in IBD

Long-term outcomes of IL‑23 inhibitors

Risque de cancer colorectal dans les MICI

Obefazimod come agente antifibrotico

Outside the gut - efficacy uf guselkumab in…

Guselkumab may improve and prevent extraintestinal…

Histo-endoscopic outcomes of upadacitinib in CD

UPA vs RISA in Crohn’s disease – a decision dilemma

Guselkumab – does it treat only the gut?

Guselkumab a objawy pozajelitowe

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Guselkumab può migliorare e prevenire le manifestazioni…

Efficacy and safety of vedolizumab + upadacitinib as…

Early and durable response with guselkumab

Vedolizumab combined with upadacitinib vs Vedolizumab…

Does colectomy reduce the risk of death in UC?

Early symptomatic response with IL-23 blockers

Mirikizumab is able to induce disease clearence in…

Long-term efficacy and safety of risankizumab in UC

Short-term effectiveness and safety of Mirikizumab in…

Etrasimod in the milder moderate UC patients

Short term transmural healing detected by US in CD…

Histo-endoscopic outcomes of guselkumab in UC

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Valutazione a breve termine della guarigione…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Est-ce que la colectomie réduit le risque de décès dans…

Efficacia e sicurezza a lungo termine di risankizumab…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Efficacia di Etrasimod in pazienti affetti da colite…

AGMB-129, Ontunisertib, new MoA in patients with…

B-cells step into the spotlight

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

Icotrokinra and systemic inflammatory burden in UC

Ontunisertib - ALK5 blockage in fistulizing CD

Appendectomy - a new therapeutic option in UC

The STENOVA Trial. Ontunisertib shows promising results…

Ikotrokinkra a stan zapalny w colitis ulcerosa

AGMB-129, Ontunisertib, nueva terapia para pacientes…

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

Impact de l’icotrokinra sur les biomarqueurs dans la…

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Apendektomie - eine neue Therapieoption bei Colitis…

AI endoscopic reads in acute severe UC change the…

ADHD and autism in IBD – the same or different story?

IBDMED מעבר לאזור הים התיכון